Tempus Wealth Planning LLC Makes New $240,000 Investment in Evolent Health, Inc. (NYSE:EVH)

Tempus Wealth Planning LLC bought a new stake in shares of Evolent Health, Inc. (NYSE:EVH) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 21,320 shares of the technology company’s stock, valued at approximately $240,000.

Several other large investors have also added to or reduced their stakes in EVH. Royce & Associates LP acquired a new stake in Evolent Health in the third quarter valued at approximately $7,070,000. Foundry Partners LLC bought a new position in shares of Evolent Health in the 3rd quarter worth $10,042,000. Salem Investment Counselors Inc. lifted its holdings in shares of Evolent Health by 53.0% in the 4th quarter. Salem Investment Counselors Inc. now owns 350,155 shares of the technology company’s stock worth $3,939,000 after purchasing an additional 121,369 shares in the last quarter. Harbor Capital Advisors Inc. grew its position in Evolent Health by 140.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 422,421 shares of the technology company’s stock valued at $11,946,000 after purchasing an additional 246,400 shares during the period. Finally, Nordea Investment Management AB increased its stake in Evolent Health by 7.0% during the 4th quarter. Nordea Investment Management AB now owns 130,453 shares of the technology company’s stock valued at $1,469,000 after purchasing an additional 8,552 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Evolent Health from $15.00 to $13.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. Royal Bank of Canada dropped their price target on shares of Evolent Health from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 14th. BTIG Research decreased their price objective on Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, December 3rd. Truist Financial dropped their target price on Evolent Health from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. Finally, JMP Securities cut their target price on Evolent Health from $27.00 to $18.00 and set a “market outperform” rating on the stock in a research report on Friday, January 10th. One investment analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $18.38.

Evolent Health Stock Performance

NYSE EVH opened at $10.27 on Wednesday. The company has a market capitalization of $1.20 billion, a PE ratio of -11.28 and a beta of 1.45. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. Evolent Health, Inc. has a 52-week low of $9.74 and a 52-week high of $35.00. The company has a 50-day simple moving average of $11.22 and a 200 day simple moving average of $19.91.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, November 7th. The technology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.30 by ($0.38). Evolent Health had a positive return on equity of 6.30% and a negative net margin of 2.93%. The company had revenue of $621.40 million for the quarter, compared to analysts’ expectations of $625.58 million. During the same quarter in the previous year, the business earned $0.19 EPS. On average, research analysts predict that Evolent Health, Inc. will post 0.24 EPS for the current year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.